OncoMatch

OncoMatch/Clinical Trials/NCT04400539

The IMmunotherapy Pleural 5-ALA PDT

Is NCT04400539 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including intrapleural photodynamic therapy with videothoracoscopy and Nivolumab for mesotheliomas pleural.

Phase 2RecruitingUniversity Hospital, LilleNCT04400539Data as of May 2026

Treatment: intrapleural photodynamic therapy with videothoracoscopy · Nivolumab — Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies in patients with malignant pleural mesothelioma

Check if I qualify

Extracted eligibility criteria

Cancer type

Mesothelioma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 2 prior lines
Min 0 prior lines

Must have received: platinum-based chemotherapy (pemetrexed) — first or second line

relapsing after one or 2 lines of treatment with platinum-based doublet of chemotherapy (including pemetrexed)

Cannot have received: anti-PD-1 therapy (nivolumab)

a previous treatment by anti-PD-1 or anti-PD-L1 antibodies for their cancer or any other cancer in the last 5 years

Cannot have received: anti-PD-L1 therapy

a previous treatment by anti-PD-1 or anti-PD-L1 antibodies for their cancer or any other cancer in the last 5 years

Cannot have received: experimental drug

treatment with experimental drug within 30 days before the start of the study

Lab requirements

Kidney function

creatinin clearance <60 ml/min excluded

Cardiac function

uncontrolled cardiac failure excluded

any other comorbidity precluding the feasibility of the therapeutic protocol: uncontrolled cardiac failure, pulmonary hypertension, liver or kidney severe dysfunction (creatinin clearance <60 ml/min), uncontrolled infection, or other disease according to the investigator

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify